These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26877615)

  • 21. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease.
    Sinitsky DM; Lemberg DA; Leach ST; Bohane TD; Jackson R; Day AS
    J Gastroenterol Hepatol; 2010 Apr; 25(4):810-6. PubMed ID: 20492339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
    Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach.
    Day AS; Whitten KE; Lemberg DA; Clarkson C; Vitug-Sales M; Jackson R; Bohane TD
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1609-14. PubMed ID: 16928225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of infliximab induction therapy on mucosal healing and clinical remission in Polish pediatric patients with moderate-to-severe Crohn's disease.
    Kierkus J; Dadalski M; Szymanska E; Oracz G; Wegner A; Gorczewska M; Szymanska S; Woynarowski M; Ryzko J
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):495-500. PubMed ID: 22387887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth and bone health in paediatric patients with Crohn's disease receiving subcutaneous tumor necrosis factor antibody.
    Pichler J; Huber WD; Aufricht C; Bidmon-Fliegenschnee B
    World J Gastroenterol; 2015 Jun; 21(21):6613-20. PubMed ID: 26074699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Remission maintained by monotherapy after biological + immunosuppressive combination for Crohn's disease in clinical practice.
    Ampuero J; Rojas-Feria M; Castro-Fernández M; Millán-Lorenzo M; Guerrero-Jiménez P; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Jan; 31(1):112-8. PubMed ID: 26173493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined azithromycin and metronidazole therapy is effective in inducing remission in pediatric Crohn's disease.
    Levine A; Turner D
    J Crohns Colitis; 2011 Jun; 5(3):222-6. PubMed ID: 21575885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
    Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
    Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Profile of pediatric Crohn's disease in Belgium.
    De Greef E; Mahachie John JM; Hoffman I; Smets F; Van Biervliet S; Scaillon M; Hauser B; Paquot I; Alliet P; Arts W; Dewit O; Peeters H; Baert F; D'Haens G; Rahier JF; Etienne I; Bauraind O; Van Gossum A; Vermeire S; Fontaine F; Muls V; Louis E; Van de Mierop F; Coche JC; Van Steen K; Veereman G; ;
    J Crohns Colitis; 2013 Dec; 7(11):e588-98. PubMed ID: 23664896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn's Disease.
    Grossi V; Lerer T; Griffiths A; LeLeiko N; Cabrera J; Otley A; Rick J; Mack D; Bousvaros A; Rosh J; Grossman A; Saeed S; Kay M; Boyle B; Oliva-Hemker M; Keljo D; Pfefferkorn M; Faubion W; Kappelman MD; Sudel B; Markowitz J; Hyams JS
    Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1748-56. PubMed ID: 25911120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autoregressive cross-lagged models of IMPACT-III and Pediatric Crohn's Disease Activity Indexes during one year infliximab therapy in pediatric patients with Crohn's disease.
    Szabó D; Kökönyei G; Arató A; Dezsőfi A; Molnár K; Müller KE; Lakatos PL; Papp M; Lovász BD; Golovics PA; Cseh A; Veres G
    J Crohns Colitis; 2014 Aug; 8(8):747-55. PubMed ID: 24434181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Therapeutic effects of combined enteral nutrition with Tripterygium Wilfordii poly-glycoside in remission induction of active adult Crohn's disease].
    Gong JF; Niu LY; Wei XW; Zhu WM; Li N; Li JS
    Zhonghua Wai Ke Za Zhi; 2009 Aug; 47(16):1213-7. PubMed ID: 19781164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission.
    Papamichael K; Vande Casteele N; Gils A; Tops S; Hauenstein S; Singh S; Princen F; Van Assche G; Rutgeerts P; Vermeire S; Ferrante M
    Clin Gastroenterol Hepatol; 2015 Jun; 13(6):1103-10. PubMed ID: 25478919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of exclusive enteral nutrition in paediatric Crohn's disease in The Netherlands.
    de Bie C; Kindermann A; Escher J
    J Crohns Colitis; 2013 May; 7(4):263-70. PubMed ID: 22820027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Over one year follow-up report for newly diagnosed pediatric Crohn's disease].
    Gao X; Shen ZY; Chen MH; Xiao YL; Yang RP; Hu PJ
    Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(16):1113-6. PubMed ID: 20646429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
    Wyneski MJ; Green A; Kay M; Wyllie R; Mahajan L
    J Pediatr Gastroenterol Nutr; 2008 Jul; 47(1):19-25. PubMed ID: 18607264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical importance of n-3 fatty acid-rich diet and nutritional education for the maintenance of remission in Crohn's disease.
    Tsujikawa T; Satoh J; Uda K; Ihara T; Okamoto T; Araki Y; Sasaki M; Fujiyama Y; Bamba T
    J Gastroenterol; 2000; 35(2):99-104. PubMed ID: 10680664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved growth and disease activity after intermittent administration of a defined formula diet in children with Crohn's disease.
    Polk DB; Hattner JA; Kerner JA
    JPEN J Parenter Enteral Nutr; 1992; 16(6):499-504. PubMed ID: 1494204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Sipponen T; Turunen U; Arkkila P; Färkkilä M
    Scand J Gastroenterol; 2013 May; 48(5):543-51. PubMed ID: 23477356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.